Please log in
to access more information


User name and Password not recognised

Home Page > The Company > Shareholders



About Bpifrance Large Venture

Bpifrance Large Venture is a €600m fund investing in healthcare, digital and green technology spaces. It funds high-growth companies with significant capital requirements for their international, industrial, or commercial development.
Large Venture is the next step in the financing cycle for venture-backed or revenue-generating companies, after early-stage VCs. Its goal is to help French national champions emerge, and help them scale globally.
Large Venture has a minimum investment size of €10 million (limited to 50% of the round), and only participates alongside professional investors. It has the ability to invest in both private and public markets.
Large Venture is a long-term, active minority investor and takes an active part in a company’s governance.


About Bpifrance and InnoBio

The public investment bank Bpifrance is the result of the merger of business funding and investment organizations OSEO, FSI, CDC Entreprises and FSI Regions. The aim of Bpifrance is to support businesses, (SMEs, mid-cap companies and larger entities of strategic importance to the French economy), from their seed capital stages up to stock market listing. They offer access to credit, collateral and equity funding. Bpifrance also provides assistance and enhanced support services for innovation, export and external growth.
InnoBio is a €173 million venture capital fund managed by Bpifrance, which is also an investor in the fund. Sanofi, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda and Boehringer-Ingelheim are among other investors. The main aim of the fund is to make equity investments in innovative companies providing technology, products and services for health care.


About Athyrium Capital Management

LP ("Athyrium") is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Athyrium is a registered investment adviser under Section 203 of the Investment Advisers Act of 1940. The Athyrium team has substantial investment experience in the healthcare sector across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. The team partners with management teams to implement creative financing solutions to companies’ capital needs.


About Financière Arbevel

Founded in 1997, Financière Arbevel, an entrepreneurial investment management company, has grown significantly since its takeover by its current owners in early 2009 – the AUM progressed from EUR 25m to EUR 1.6bn as of today (of which EUR 732m under the umbrella SICAV “Pluvalca” comprising of 9 sub-funds). The company currently employs a total of 34 staff members, of which 13 are dedicated to fund management/investment research.
Financière Arbevel is recognized for its expertise within the small & mid cap asset class. It is a research-driven organization with a strong emphasis on fundamental financial and strategic analysis, close relationships with the top management teams of listed companies (more than 1000 company meetings last year) and a permanent quest for new investment themes offering structural growth opportunities. The digitalization, fintech, Industry 4.0, or the ageing of the world population are some of its favourite investment themes. The Company ensures it closely follows the latest developments within this sector, by participating in various conferences, trade fairs, sector-specific thematic events and by meeting regularly with listed companies. Its small & mid cap DNA is spread across various strategies under the PLUVALCA family of funds with a cross-asset approach comprising of our core equity funds, thematic equity funds, fixed income and diversified/flexible allocation funds.
In 2015, the Norwegian sovereign wealth fund chose Financière Arbevel to manage its French equity mandate.
In 2018, Financière Arbevel pursued its development by launching its first European private equity fund (FPCI form or “Professional private equity investment fund”) with a cross-over approach focused on the non-listed life-science industry, with the aim to accompany a limited number of biotechnology start-ups in their development.


About Gimv

Gimv is a European investment company with over three decades of experience in private equity and venture capital. Gimv is listed on Euronext Brussels and currently manages around €1.8 billion (including investment partnerships) of investments in 50 portfolio companies. As a recognized market leader in selected investment platforms, Gimv dentifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are: Consumer 2020, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of Benelux, France and Germany and can count on an extended international network of experts.


About Lundbeckfond Ventures

Lundbeckfond Ventures is a part of the asset management subsidiary of The Lundbeck Foundation which in addition to substantial financial assets has controlling ownerships in H.Lundbeck A/S, ALK-Abelló A/S and Falck A/S.
Lundbeckfond Ventures has an evergreen structure and invests around $60 million annually in life science companies. The Lundbeckfond Ventures team is located in Copenhagen, Denmark, and is active in both Europe and the USA.


About Invesco

Invesco is an independent investment management firm dedicated to delivering an investment experience that helps people get more out of life. We are privileged to manage more than $888.2 billion in assets on behalf of clients worldwide (as of December 31, 2018 ).
Invesco has:
- Specialized investment teams managing investments across a comprehensive range of asset classes, investment styles and geographies.
- Over 7,000 employees focused on client needs across the globe.
- Proximity to their clients with an on-the-ground presence in 25 countries.
- Solid financials, an investment grade debt rating, and a strong balance sheet.